Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Betty Lawrence"'
Autor:
Catherine A. Bliss, Betty Lawrence
Publikováno v:
Online Learning, Vol 13, Iss 2 (2019)
Asynchronous text based discussion boards are included in many online courses, however strategies to compare their use within and between courses, from a disciplinary standpoint, have not been well documented in the literature. The goal of this proje
Externí odkaz:
https://doaj.org/article/da1d5c13af5b489b8516bd1ba7cf988d
Autor:
Catherine A. Bliss, Betty Lawrence
Publikováno v:
Online Learning, Vol 13, Iss 4 (2019)
Methods for characterizing asynchronous text-based discussions have received significant attention in the literature. In this study, we examine student and instructor posts made in seventeen undergraduate mathematics courses over the duration of a fi
Externí odkaz:
https://doaj.org/article/ada9fec3a11f47068b5a7b9589a62482
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Steve Rosenfeld, Xiaolin Wang, Betty Lawrence, Mona Shing, Robert M. Fielding, Jean Paul Castaigne, Patrick Y. Wen, Christina A. Meyers, April F. Eichler, Eric T. Wong, Andrew Brenner, David Schiff, John Sarantopoulos, Jan Drappatz, Tom Mikkelsen, Morris D. Groves, Stephen M. Kelsey, Kelly Elian
Publikováno v:
Clinical Cancer Research. 19:1567-1576
Purpose: GRN1005 is a peptide–drug conjugate with the ability to penetrate the blood–brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor–related protein-1. We conducted a first-in-human phase I trial of GRN1005
Publikováno v:
Open Learning: The Journal of Open, Distance and e-Learning. 26:135-146
Laboratory experiments are often considered the defining characteristic of science courses. Such activities provide students with real‐world contexts for applying scientific concepts, while also allowing them to develop scientific ways of thinking
Autor:
Betty Lawrence, Alessia Sagazio, Danilo Fintini, Roberto Salvatori, Jean Paul Castaigne, Lawrence A. Frohman, Maria Alba
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 291:E1290-E1294
Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice w
Autor:
Jean-Paul Castaigne, Betty Lawrence, Lawrence A. Frohman, Catherine Gagnon, Sam L Teichman, Ann Neale
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:799-805
Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action. Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHR
Autor:
Anthony D. Elias, Razelle Kurzrock, John Sarantopoulos, Santosh Kesari, Susan E. Bates, Jean-Paul Castaigne, Betty Lawrence, Lee S. Schwartzberg, Nan Lin, Carey K. Anders, Nashat Y. Gabrail, Vihra Iordanova
Publikováno v:
Journal of Clinical Oncology. 32:2523-2523
2523 Background: ANG1005 consists of 3 paclitaxel molecules covalently linked to a proprietary 19 AA peptide that targets the LRP1 receptor. This receptor is highly expressed on endothelial cells o...
Autor:
Theresa Fauconnier, Ernest Wong, Dennis Eshima, Russell A. Bell, Linda F. L. Lu, Samantha Bennett, John R. Thornback, Betty Lawrence
Publikováno v:
Inorganic chemistry. 40(22)
The Tc-99m complex of dimethylglycyl-l-seryl-l-cysteinyl(acm)-glycl-l-threonyl-l-lysyl-l-prolyl-l-prolyl-l-arginine (RP128) is a radiopharmaceutical designed for imaging sites of inflammation. RP128 and its rhenium(V) and technetium(V) oxo complexes
Autor:
Morris D. Groves, Yijing Shen, Tom Mikkelsen, Xiaolin Wang, Razelle Kurzrock, Steven S. Rosenfeld, Nash Gabrail, David Schiff, Mona Shing, Betty Lawrence, Patrick Y. Wen, Jean-Paul Castaigne, Andrew Brenner, Jan Drappatz, John Sarantopoulos
Publikováno v:
Molecular Cancer Therapeutics. 10:B49-B49
Background: Treatment of brain tumors is an unmet medical need due to the inability of most anti-cancer agents to effectively cross the blood brain barrier (BBB). GRN1005 (formerly ANG1005) is a peptide-drug conjugate (PDC) consisting of three molecu